Free tool
Drug Trial Radar: Ophthalmology
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
39
Active, not recruiting, industry sponsors, Ophthalmology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed464
39 trials
Showing 1 to 25, recently updated first.
- Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle GlaucomaPivotal-lookingActive, not recruiting
Omikron Italia S.r.l.Industry
NCT05710198 · 873 participants · Start Dec 11, 2023 · Primary completion Jul 1, 2029
Drug: Citicoline eye drops 2%; Placebo · For: Glaucoma, Open-Angle
Sites: Milan, Italy
- Nipocalimab in Moderate to Severe Sjogren's DiseasePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06741969 · 655 participants · Start Dec 4, 2024 · Primary completion Feb 4, 2027
Drug: Nipocalimab; Placebo and 1 more · For: Sjogrens Syndrome
Sites: Chula Vista, California; La Palma, California; Mission Viejo, California · 254 sites in all
- A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPivotal-lookingActive, not recruiting
EyeBiotech Ltd.Industry
NCT06571045 · 984 participants · Start Aug 7, 2024 · Primary completion Jul 14, 2026
Drug: Ranibizumab; Remigromig · For: Diabetic Macular Edema (DME)
Sites: Scottsdale, Arizona; Fayetteville, Arkansas; Springdale, Arkansas · 183 sites in all
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56Pivotal-lookingActive, not recruiting
EyePoint Pharmaceuticals, Inc.Industry
NCT06668064 · 400 participants (planned) · Start Oct 22, 2024 · Primary completion Jul 13, 2026
Drug: EYP-1901; Aflibercept (2.0 mg) · For: Wet Age Related Macular Degeneration; wAMD
Sites: Phoenix, Arizona; Springdale, Arkansas; Bakersfield, California · 76 sites in all
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56Pivotal-lookingActive, not recruiting
EyePoint Pharmaceuticals, Inc.Industry
NCT06683742 · 400 participants (planned) · Start Nov 27, 2024 · Primary completion Sep 9, 2026
Drug: EYP-1901; Aflibercept (2.0 mg) · For: Wet Age Related Macular Degeneration; wAMD
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 113 sites in all
- A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKPivotal-lookingActive, not recruiting
Kodiak Sciences IncIndustry
NCT06556368 · 667 participants · Start Aug 23, 2024 · Primary completion Sep 2, 2026
Drug: Tarcocimab tedromer; Tabirafusp tedromer and 1 more · For: Wet Age-related Macular Degeneration
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 72 sites in all
- COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPivotal-lookingActive, not recruiting
EyePoint Pharmaceuticals, Inc.Industry
NCT07449936 · 240 participants (planned) · Start Feb 16, 2026 · Primary completion Oct 2027
Drug: EYP-1901; Aflibercept (2.0 mg) · For: Diabetic Macular Edema; DME; Diabetic Macular Edema (DME)
Sites: Bakersfield, California; Encino, California; Glendale, California · 73 sites in all
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPivotal-lookingActive, not recruiting
EyePoint Pharmaceuticals, Inc.Industry
NCT07449923 · 240 participants (planned) · Start Feb 9, 2026 · Primary completion Oct 2027
Drug: EYP-1901; Aflibercept (2.0 mg) · For: Diabetic Macular Edema; DME; Diabetic Macular Edema (DME)
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 70 sites in all
- A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPivotal-lookingActive, not recruiting
EyeBiotech Ltd.Industry
NCT06957080 · 1,054 participants · Start Apr 16, 2025 · Primary completion Jan 11, 2027
Drug: Remigromig; Ranibizumab · For: Diabetic Macular Edema (DME)
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 164 sites in all
- A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04657289 · 451 participants · Start Jul 14, 2021 · Primary completion Feb 4, 2027
Drug: Ranibizumab · For: Neovascular Age-related Macular Degeneration (nAMD)
Sites: Capital Federal, Argentina; Rosario, Argentina; Albury, Australia · 104 sites in all
- A Clinical Study Evaluating Licaminlimab for Dry Eye DiseasePivotal-lookingActive, not recruiting
OculisIndustry
NCT07548632 · 160 participants (planned) · Start Apr 16, 2026 · Primary completion Dec 2026
Drug: licaminlimab · For: Dry Eye Disease (DED)
Sites: Aliso Viejo, California; Garden Grove, California; Glendale, California · 14 sites in all
- 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationPivotal-lookingActive, not recruiting
4D Molecular TherapeuticsIndustry
NCT06864988 · 480 participants (planned) · Start Mar 3, 2025 · Primary completion Jun 2027
Drug: 4D-150 IVT (3E10 vg/eye); EYLEA® (aflibercept) Injection 2 mg (0.05mL) · For: Macular Neovascularization Secondary to Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Scottsdale, Arizona; Springdale, Arkansas · 94 sites in all
- A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05985915 · 612 participants · Start Oct 27, 2023 · Primary completion Apr 22, 2033
Drug: Ianalumab (VAY736) · For: Sjogrens Syndrome
Sites: Fullerton, California; La Palma, California; Van Nuys, California · 198 sites in all
- A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DMEPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04108156 · 672 participants · Start Sep 30, 2019 · Primary completion Jul 20, 2027
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab; Intravitreal Ranibizumab 0.5 mg Injection and 1 more · For: Diabetic Macular Edema
Sites: Mesa, Arizona; Phoenix, Arizona; Bakersfield, California · 89 sites in all
- A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)Pivotal-lookingActive, not recruiting
Annexon, Inc.Industry
NCT06510816 · 659 participants · Start Jul 30, 2024 · Primary completion Jul 31, 2027
Drug: Vonaprument · For: Geographic Atrophy
Sites: Scottsdale, Arizona; Beverly Hills, California; Fullerton, California · 132 sites in all
- Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR GenePivotal-lookingActive, not recruiting
MeiraGTx Ocular UK LtdIndustry
NCT04794101 · 97 participants · Start Dec 4, 2020 · Primary completion Sep 20, 2029
Drug: Genetic: AAV5-hRKp.RPGR Intermediate Dose; Genetic: AAV5-hRKp.RPGR Low Dose · For: X-Linked Retinitis Pigmentosa
Sites: La Jolla, California; Los Angeles, California; Palo Alto, California · 28 sites in all
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)Pivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06491914 · 1,126 participants · Start Jul 24, 2024 · Primary completion Aug 26, 2025
Drug: Aflibercept 8 mg · For: Neovascular Age-Related Macular Degeneration; Diabetic Macular Edema
Sites: Arcadia, California; Bakersfield, California; Beverly Hills, California · 54 sites in all
- ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)Pivotal-lookingActive, not recruiting
Stealth BioTherapeutics Inc.Industry
NCT06373731 · 313 participants · Start May 30, 2024 · Primary completion Aug 2027
Drug: Elamipretide; Placebo · For: Age Related Macular Degeneration (ARMD)
Sites: Phoenix, Arizona; Sun City, Arizona; Huntington Beach, California · 53 sites in all
- A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05562947 · 68 participants (planned) · Start Jun 17, 2024 · Primary completion Jun 30, 2027
Drug: Ranibizumab (10 mg/mL) · For: Neovascular Age-related Macular Degeneration; nAMD
Sites: Beijing, China; Chengdu, China; Guangzhou, China · 14 sites in all
- A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior UveitisPivotal-lookingActive, not recruiting
VivaVision Biotech, IncIndustry
NCT07136805 · 154 participants · Start Nov 25, 2025 · Primary completion Dec 31, 2026
Drug: VVN461 Ophthalmic Solution 1.0%; 1.0% prednisolone acetate · For: Non-infectious Anterior Uveitis
Sites: Chongqing, China; Beijing, China
- Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT05407636 · 735 participants · Start Jan 13, 2022 · Primary completion Oct 2026
Drug: Aflibercept (EYLEA®) · For: AMD; nAMD; Wet Age-related Macular Degeneration and 3 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Bakersfield, California · 181 sites in all
- A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseasePivotal-lookingActive, not recruiting
OcugenIndustry
NCT05956626 · 51 participants (planned) · Start Aug 25, 2023 · Primary completion Sep 28, 2026
Drug: OCU410ST · For: Stargardt Disease
Sites: Phoenix, Arizona; Sacramento, California; Gainesville, Florida · 14 sites in all
- Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromePivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05349214 · 506 participants · Start Aug 4, 2022 · Primary completion May 13, 2025
Drug: VAY736 · For: Sjogren Syndrome
Sites: Fullerton, California; La Palma, California; Brandon, Florida · 146 sites in all
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular DegenerationPivotal-lookingActive, not recruiting
Adverum Biotechnologies, Inc.Industry
NCT06856577 · 311 participants · Start Feb 28, 2025 · Primary completion Dec 22, 2026
Drug: Aflibercept · For: Neovascular Age-Related Macular Degeneration (nAMD); Wet AMD
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 75 sites in all
- A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in ChinaPivotal-lookingActive, not recruiting
Santen Pharmaceutical Co., Ltd.Industry
NCT06666855 · 345 participants · Start Nov 28, 2024 · Primary completion Aug 31, 2026
Drug: DE-117B Eye Drops; Latanoprost · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Beijing, China; Guangzhou, China; Guiyang, China · 24 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.